ProKidney CEO cites 'significant progress' after regenerative medicine company loses $163M in 2024

Triad Business Journal

Mar 17, 2025

Most of ProKidney's money went toward R&D as it attempts to get its first-in-class cellular therapy for Chronic Kidney Disease to market. See what CEO Bruce Culleton says about 202…